Physician profile
Mark Barlow
NPI 1134122856
$1,497.35
in general payments reported to CMS, 2019-2025
14 companies · $14.37 in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $180 · 2020: $21.47 · 2021: $171 · 2022: $492 · 2023: $214 · 2024: $405 · 2025: $14.37.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $633.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $632.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mentor Worldwide LLC | $417.26 | 2021-2024 | Mentor Memorygel Resterilizable Gel Sizer |
| Sientra, INC. | $344.27 | 2019-2022 | |
| Merz North America, INC. | $219.05 | 2021-2022 | |
| Tela Bio, INC. | $158.24 | 2024 | Ovitex 2s |
| Depuy Synthes Sales INC. | $106.33 | 2023 | Matrixmandible, Trumatch |
| Heron Therapeutics, INC. | $44.79 | 2023 | Zynrelef |
| Davol INC. | $41.67 | 2022 | |
| Allergan, INC. | $38.28 | 2021 | |
| Integra Lifesciences Corporation | $34.51 | 2023-2025 | Integra, Integra Dermal Regeneration Template, Omnigraft |
| Abbvie INC. | $34.15 | 2024 | |
| Pacira Pharmaceuticals Incorporated | $17.52 | 2024 | Exparel |
| Smith+Nephew, INC. | $15.16 | 2022 | |
| Coopersurgical, INC. | $13.72 | 2021 | |
| Axogen | $12.40 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Barlow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.